Metabolites

Journal Browser

► Journal Browser

Special Issue Editors

Dr. Gloria Formoso

E-Mail Website
Guest Editor

Department of Medicine and Aging Sciences, University of Chieti, 66100 Chieti, Italy
Interests: diabetes therapies; diabetes macrovalscular complications; endothelial dysfunction

Dr. Maria P.A. Baldassarre

E-Mail
Guest Editor

Dipartimento di Scienze Biomediche ed Oncologia Umana (DIMO), University of Chieti,66100 Chieti, Italy
Interests: diabetes therapies; vascular biomarker; endothelial dysfunction

Special Issue Information

Dear Colleagues,

Despite the strong evidence supporting their efficacy and safety, use of Glucagon-like peptide-1 receptor agonists (GLP-1RAs) as well as Sodium/glucose cotransporter-2 inhibitors (SGLT2i) is still relatively limited. This might be due to clinicians’ resistance in relying solely on data gathered from randomized controlled clinical trials. Data obtained in actual clinical practice might help in reassuring clinicians about the effectiveness, safety, and ease of use of this class of drugs in a real-world setting. Furthermore, considering the proven cardiovascular benefit observed with these classes of drugs, it would be interesting to monitor the cardiovascular benefit by evaluating circulating biomarkers of vascular damage/benefit in real life.

This special issue of Metabolites entitled “New Insights from Type 2 Diabetes Treatments in Real Life” aims to highlight the safety and the effectiveness of GLP-1RAs and SGLT2i on glycaemic and metabolic endpoints. Furthermore, as circulating biomarker of cardiovascular damage/benefit may be predictors of treatment response in patients with diabetes in a real-world setting, studies including evaluation of biomarkers of vascular state are also appreciated.

Different types of manuscript submission, including original research articles and updated reviews are welcome.

Dr. Gloria Formoso
Dr. Maria P.A. Baldassarre
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Metabolites is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

Glucagon-like peptide-1 receptor agonists
Sodium/glucose cotransporter-2 inhibitors inhibitors
Diabetes
Biomarkers
Real world evidence/Clinical Practice

Published Papers (2 papers)

Download All Papers

Review

Jump to: Other

11 pages, 1892 KiB

Open AccessReview

Sodium-Glucose Cotransporter-2 Inhibitors Improve Cardiovascular Dysfunction in Type 2 Diabetic East Asians

by Muhammad Afzal, Fahad A. Al-Abbasi, Muhammad Shahid Nadeem, Sultan Alshehri, Mohammed M. Ghoneim, Syed Sarim Imam, Waleed Hassan Almalki and Imran Kazmi

Metabolites 2021, 11(11), 794; https://doi.org/10.3390/metabo11110794 - 21 Nov 2021

Viewed by 2135

Abstract

In East Asians, the incidence of type 2 DM (T2DM) has increased as a result of major alterations in life. Cardiovascular problems are more likely in those with T2DM. Sodium-glucose cotransporter-2 (SGLT2) inhibitors are novel insulin-independent antihyperglycemic drugs that limit renal glucose reabsorption and thereby improve glycemic control. They are used alone or in combination with insulin and other antihyperglycemic medications to treat diabetes, and they are also helpful in protecting against the progression of complications. This review has evaluated the available evidence not only on the efficacy of SGLT2 inhibitors in T2DM, but also on their favourable cardiovascular events in East Asians. DM is an independent risk factor for cardiovascular diseases. As a result, in addition to glycemic control in diabetes management, the therapeutic goal in East Asian diabetic patients should be to improve adverse cardiovascular outcomes. Besides establishing antidiabetic effects, several studies have reported cardioprotective benefits of SGLT2 inhibitors via numerous pathways. SGLT2 inhibitors show promising antidiabetic drugs with potential cardiovascular advantages, given that a high number of diabetic patients in East Asia have co-existing cardiovascular disorders. Despite significant positive results in favour of SGLT2, more research is needed to determine how SGLT2 inhibitors exert these impressive cardiovascular effects. Full article

(This article belongs to the Special Issue New Insights from Type 2 Diabetes Treatments in Real Life, Focus on GLP-1RAs and SGLT2i)

► Show Figures

Graphical abstract

Other

Jump to: Review

18 pages, 13721 KiB

Open AccessSystematic Review

Cardiovascular and Renal Effectiveness of GLP-1 Receptor Agonists vs. Other Glucose-Lowering Drugs in Type 2 Diabetes: A Systematic Review and Meta-Analysis of Real-World Studies

by Irene Caruso, Angelo Cignarelli, Gian Pio Sorice, Annalisa Natalicchio, Sebastio Perrini, Luigi Laviola and Francesco Giorgino

Metabolites 2022, 12(2), 183; https://doi.org/10.3390/metabo12020183 - 15 Feb 2022

Cited by 35 | Viewed by 4612

Abstract

Cardiovascular outcome trials (CVOT) showed that treatment with glucagon-like peptide-1 receptor agonists (GLP-1RA) is associated with significant cardiovascular benefits. However, CVOT are scarcely representative of everyday clinical practice, and real-world studies could provide clinicians with more relatable evidence. Here, literature was thoroughly searched to retrieve real-world studies investigating the cardiovascular and renal outcomes of GLP-1RA vs. other glucose-lowering drugs and carry out relevant meta-analyses thereof. Most real-world studies were conducted in populations at low cardiovascular and renal risk. Of note, real-world studies investigating cardio-renal outcomes of GLP-1RA suggested that initiation of GLP-1RA was associated with a greater benefit on composite cardiovascular outcomes, MACE (major adverse cardiovascular events), all-cause mortality, myocardial infarction, stroke, cardiovascular death, peripheral artery disease, and heart failure compared to other glucose-lowering drugs with the exception of sodium-glucose transporter-2 inhibitors (SGLT-2i). Initiation of SGLT-2i and GLP-1RA yielded similar effects on composite cardiovascular outcomes, MACE, stroke, and myocardial infarction. Conversely, GLP-1RA were less effective on heart failure prevention compared to SGLT-2i. Finally, the few real-world studies addressing renal outcomes suggested a significant benefit of GLP-1RA on estimated glomerular filtration rate (eGFR) reduction and hard renal outcomes vs. active comparators except SGLT-2i. Further real-world evidence is needed to clarify the role of GLP-1RA in cardio-renal protection among available glucose-lowering drugs. Full article

(This article belongs to the Special Issue New Insights from Type 2 Diabetes Treatments in Real Life, Focus on GLP-1RAs and SGLT2i)

► Show Figures